Workspaces
Log in Sign up

Bristol Myers Squibb's Zenbexus Wins Historic First-in-Class FDA Approval in Multiple Myeloma

Updated

Sources

Bristol Myers Squibb's Zenbexus Wins Historic First-in-Class FDA Approval in Multiple Myeloma

On August 13, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Bristol Myers Squibb's Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone (IberDd / ZDd) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). Eligible patients must have received at least one prior line of therapy, including both a proteasome inhibitor and an immunomodulatory agent.

Zenbexus is the first-ever approved cereblon-modulating protein degrader (CELMoD), representing a major therapeutic milestone for targeted protein degradation (TPD) platforms. It is designed to bind cereblon to induce rapid and potent degradation of the transcription factors Ikaros and Aiolos, generating direct antimyeloma and immune-stimulatory effects that overcome resistance to traditional immunomodulatory drugs (IMiDs) like lenalidomide and pomalidomide.

A Regulatory Milestone: First Accelerated Approval Driven Directly by MRD-Negativity

In addition to its therapeutic novelty, Zenbexus marks a historic regulatory shift as the first new drug in multiple myeloma to win accelerated approval based directly on minimal residual disease (MRD)-negative complete response (CR) as a surrogate endpoint. The FDA's adoption of MRD-negativity as a surrogate endpoint is intended to drastically accelerate the drug approval timeline in the multiple myeloma setting compared to traditional, longer-term outcomes like progression-free survival (PFS). Continued approval for this indication is contingent upon verification of clinical benefit (such as PFS) in confirmatory trials.

The approval was supported by efficacy and safety data from the ongoing Phase 3 EXCALIBER-RRMM trial (NCT04975997). The primary efficacy population for accelerated approval comprised the first 420 randomized patients. Efficacy findings showed:

  • Zenbexus Combination Arm (IberDd; n=207): Achieved an MRD-negative CR rate of 41% (95% CI: 34%–48%).
  • Standard-of-Care Comparator Arm (DVd; n=213): Achieved an MRD-negative CR rate of 21% (95% CI: 15%–27%).
  • This represents an approximate two-fold improvement in achieving deep, undetectable levels of residual disease (p < 0.0001).
Dosing, Safety, and Restricted REMS Distribution

The recommended dosage of Zenbexus is 1.0 mg taken orally once daily on Days 1 through 21 of a 28-day cycle, in combination with subcutaneous daratumumab and hyaluronidase-fihj and oral dexamethasone.

Because of its mechanism of action, Zenbexus carries a Boxed Warning for embryo-fetal toxicity and serious venous and arterial thromboembolism (including deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke). To mitigate these risks, Zenbexus is available exclusively through a restricted distribution program called the ZENBEXUS REMS program. Other major safety warnings include severe neutropenia (reported in 90.2% of patients in the IberDd arm, with 53.4% experiencing Grade 4 neutropenia) and serious or fatal infections (occurring in 78.9% of patients).

"The FDA’s approval of Zenbexus (iberdomide) marks the anticipated arrival of a new therapeutic class for relapsed or refractory multiple myeloma and has the potential to make a meaningful difference for patients. The strong results observed with the CELMoD-based combination within a familiar triplet approach creates the potential for a new treatment foundation in multiple myeloma." — Dr. Sagar Lonial, MD, FACP, FASCO, EXCALIBER-RRMM Lead Investigator, quoted in BMS Press Release

"As the first approved CELMoD, Zenbexus marks the arrival of a new treatment class and is an important milestone in our efforts to expand what is possible for patients with multiple myeloma. And we believe this is only the beginning. This approval validates years of scientific research and strengthens our confidence in the potential of this approach..." — Cristian Massacesi, MD, Chief Medical Officer and Head of Development, Bristol Myers Squibb, quoted in BMS Press Release

Part of

This finding is an example of a pattern recurring across your work:

Revision history

  • Update the Zenbexus multiple myeloma accelerated approval note with detailed Phase 3 EXCALIBER-RRMM efficacy data, regulatory significance of the MRD-negativity surrogate endpoint, dosing, and boxed warnings.
    · by the agent
  • Update the Zenbexus multiple myeloma accelerated approval note with detailed Phase 3 EXCALIBER-RRMM efficacy data, regulatory significance of the MRD-negativity surrogate endpoint, dosing, and boxed warnings.
    · by the agent
  • Update the Zenbexus multiple myeloma accelerated approval note with detailed Phase 3 EXCALIBER-RRMM efficacy data, regulatory significance of the MRD-negativity surrogate endpoint, dosing, and boxed warnings.
    · by the agent
  • Update the Zenbexus multiple myeloma accelerated approval note with detailed Phase 3 EXCALIBER-RRMM efficacy data, regulatory significance of the MRD-negativity surrogate endpoint, dosing, and boxed warnings.
    · by the agent
  • Update the Zenbexus multiple myeloma accelerated approval note with detailed Phase 3 EXCALIBER-RRMM efficacy data, regulatory significance of the MRD-negativity surrogate endpoint, dosing, and boxed warnings.
    · by the agent
  • Update the Zenbexus multiple myeloma accelerated approval note with detailed Phase 3 EXCALIBER-RRMM efficacy data, regulatory significance of the MRD-negativity surrogate endpoint, dosing, and boxed warnings.
    · by the agent
  • Update the Zenbexus multiple myeloma accelerated approval note with detailed Phase 3 EXCALIBER-RRMM efficacy data, regulatory significance of the MRD-negativity surrogate endpoint, dosing, and boxed warnings.
    · by the agent
  • Update the Zenbexus multiple myeloma accelerated approval note with detailed Phase 3 EXCALIBER-RRMM efficacy data, regulatory significance of the MRD-negativity surrogate endpoint, dosing, and boxed warnings.
    · by the agent
  • Update the Zenbexus multiple myeloma accelerated approval note with detailed Phase 3 EXCALIBER-RRMM efficacy data, regulatory significance of the MRD-negativity surrogate endpoint, dosing, and boxed warnings.
    · by the agent
  • Updated without a stated reason.
    · by the agent